Blocking interleukin 12 may protect insulin-producing cells and blood vessels in type 2 diabetes.
Interleukin 12 disruption provides beta cell and microvessel protection in type 2diabetes
This study is looking at how a substance called IL-12 affects people with type 2 diabetes, specifically how it might harm insulin-producing cells and blood vessels, and it hopes to find ways to block IL-12 to help protect these important parts of the body and reduce diabetes-related health issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Old Dominion University NIH-funded |
| Lab location | 1 site (Norfolk, United States) |
| Project ID | NIH-11123521 on NIH RePORTER |
What this research studies
This research investigates the role of interleukin 12 (IL-12) in type 2 diabetes and its impact on insulin-producing beta cells and blood vessel function. The study aims to understand how inhibiting IL-12 can prevent damage to these cells and reduce complications associated with diabetes, such as heart disease and kidney damage. By exploring the mechanisms behind IL-12's effects, the research seeks to identify new treatment targets that could improve overall health for patients with type 2 diabetes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 2 diabetes who are experiencing complications related to beta cell failure and microvascular dysfunction.
Not a fit: Patients without type 2 diabetes or those whose condition is not related to beta cell or microvascular issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that protect vital cells and improve health outcomes for individuals with type 2 diabetes.
How similar studies have performed: While the specific approach of targeting IL-12 in type 2 diabetes is novel, similar research has shown that targeting inflammatory cytokines can lead to improvements in related conditions.
Where this research is happening
Norfolk, United States
- Old Dominion University — Norfolk, United States (Active)
Researchers
- Principal investigator: Matrougui, Khalid — Old Dominion University
- Study coordinator: Matrougui, Khalid
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.